Dr. Ramiro Sanchez, M.D. is the Chief Medical Officer of Cerevel Therapeutics Holdings, Inc. (CERE), where he oversees clinical development and medical strategy for the company’s neuroscience-focused pipeline.( He has served as Cerevel’s Chief Medical Officer under an employment agreement effective January 14, 2019, and is a significant corporate insider, holding hundreds of thousands of Cerevel shares and executing regular Form 4–reported transactions in the company’s stock.( Public filings list him as a key executive officer of Cerevel, responsible for guiding the design and execution of clinical programs in areas such as epilepsy, anxiety, and substance use disorder.(

According to SEC and market data services, Dr. Sanchez is an experienced physician–executive with a long-standing career in central nervous system drug development, reflected in his senior leadership roles and substantial equity position at Cerevel.( Insider trading records show that 2023 was his most active year in terms of both acquiring and disposing of Cerevel shares, with multi-million-dollar transaction values, underscoring his role as a core member of the leadership team.( He holds a medical degree (M.D.), and is identified in investor-relations materials specifically as Dr. Ramiro Sanchez, M.D., Chief Medical Officer of Cerevel Therapeutics.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.